DIKUL - logo
E-resources
Full text
Peer reviewed Open access
  • Anti-C5 Antibody Tesidoluma...
    Adams, Andrew B; Lovasik, Brendan P; Faber, David A; Burlak, Christopher; Breeden, Cynthia; Estrada, Jose L; Reyes, Luz M; Vianna, Rodrigo M; Tector, Matthew F; Tector, Alfred J

    Annals of surgery, 09/2021, Volume: 274, Issue: 3
    Journal Article

    Pig-to-primate renal xenotransplantation is plagued by early antibody-mediated graft loss which precludes clinical application of renal xenotransplantation. We evaluated whether temporary complement inhibition with anti-C5 antibody Tesidolumab could minimize the impact of early antibody-mediated rejection in rhesus monkeys receiving pig kidneys receiving costimulatory blockade-based immunosuppression. Double (Gal and Sda) and triple xenoantigen (Gal, Sda, and SLA I) pigs were created using CRISPR/Cas. Kidneys from DKO and TKO pigs were transplanted into rhesus monkeys that had the least reactive crossmatches. Recipients received anti-C5 antibody weekly for 70 days, and T cell depletion, anti-CD154, mycophenolic acid, and steroids as baseline immunosuppression (n = 7). Control recipients did not receive anti-C5 therapy (n = 10). Temporary anti-C5 therapy reduced early graft loss secondary to antibody-mediated rejection and improved graft survival (P < 0.01). Deleting class I MHC (SLA I) in donor pigs did not ameliorate early antibody-mediated rejection (table). Anti-C5 therapy did not allow for the use of tacrolimus instead of anti-CD154 (table), prolonging survival to a maximum of 62 days. Inhibition of the C5 complement subunit prolongs renal xenotransplant survival in a pig to non-human primate model.